What’s New in Genetic Testing for Breast Cancer & Ovarian Cancer?

What’s New in Genetic Testing for Breast Cancer?

genetic testing for breast cancerGenetic testing for breast cancer and ovarian cancer has evolved into an important way to determine your cancer risk, especially if cancer runs in your family history.

Many patients often refer to BRCA1 & BRCA2 genetic testing to help us determine if we carry this genetic mutation. The significance? Carrying the mutated BRCA1 & BRCA2 gene makes the likelihood of your family members carrying the same mutation higher. Unfortunately, this also increases your risk of developing cancer.

Watch the video below as Arizona Oncology’s Dr. Mike Janicek shares what’s new in genetic testing for breast cancer and ovarian cancer.

Transcript

Mike F. Janicek:  Genetic testing is very different than it was even a few years ago.  This all started with the Supreme Court decision last June that struck down the patent Myriad Genetics that own the patent on the BRCA1 and BRCA2 genes and overnight labs I had run 20 other gene panels that are also important for breast, ovarian, and other cancers, we are suddenly able to test BRCA1 and BRCA2. 

Before we had to make a choice, test for BRCA1 and BRCA2 and if it is negative you stuck because insurance wouldn’t pay for the other genes.  Now with one decision by the Supreme Court overnight, we got what’s called gene panels, so we are testing 10 times more genes over 20 genes now and half the cost, so it has been a phenomenal revolution since that Supreme Court decision in terms of our ability to test patients for more genes at less cost.